1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,600 | 14,000 | 15:57 | |
| 13,600 | 14,000 | 15:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FORTREA Aktie jetzt für 0€ handeln | |||||
| Do | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 04.12. | SCTbio and Fortrea form strategic partnership to accelerate cell therapies | 1 | Investing.com | ||
| 04.12. | Fortrea Holdings Inc: SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery | 179 | GlobeNewswire (Europe) | PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global... ► Artikel lesen | |
| 24.11. | Fortrea completes debt tender offer, reducing outstanding notes | 3 | Investing.com | ||
| 24.11. | Fortrea Holdings Inc: Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand | 1 | GlobeNewswire (USA) | ||
| 20.11. | Fortrea Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11. | Truist Securities raises Fortrea stock price target to $12 from $7 on Q3 results | 2 | Investing.com | ||
| 05.11. | Fortrea Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.11. | Fortrea Q3 2025 slides: Strategic initiatives drive stock surge despite earnings miss | 4 | Investing.com | ||
| 05.11. | Fortrea Holdings Inc. Q3 Earnings Summary | 1 | RTTNews | ||
| 05.11. | Fortrea Holdings reports mixed Q3 results; updates FY25 outlook | 2 | Seeking Alpha | ||
| 05.11. | Fortrea Holdings Inc: Fortrea Reports Third Quarter 2025 Results | 131 | GlobeNewswire (Europe) | For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income... ► Artikel lesen | |
| 05.11. | Fortrea Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Fortrea launches $75.7 million debt tender offer for senior notes | 1 | Investing.com | ||
| 20.10. | Fortrea Holdings Inc: Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt | 2 | GlobeNewswire (USA) | ||
| 02.10. | Where Fortrea Holdings Stands With Analysts | 9 | Benzinga.com | ||
| 22.09. | Fortrea names William Sharbaugh to board of directors | 2 | Investing.com | ||
| 22.09. | Fortrea beruft William Sharbaugh in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 22.09. | Fortrea Holdings Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 22.09. | Fortrea Holdings Inc: Fortrea Appoints William Sharbaugh to Board of Directors | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 48,600 | +0,21 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 38,455 | -0,39 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AMGEN | 271,85 | +0,57 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,768 | +1,16 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 300,60 | -0,86 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| ILLUMINA | 115,82 | -0,33 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,600 | 0,00 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| AAP IMPLANTATE | 1,350 | -0,74 % | aap Implantate: Kapitalerhöhung per Privatplatzierung | Die aap Implantate AG hat eine Barkapitalerhöhung um 788.150 Euro beschlossen, wodurch sich das Grundkapital auf 14,7 Millionen Euro erhöht. Die Maßnahme erfolgt durch die Ausgabe von 788.150 neuen... ► Artikel lesen | |
| OCUGEN | 1,140 | +2,56 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| SANGAMO THERAPEUTICS | 0,390 | -0,28 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,232 | +1,06 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| DEFENCE THERAPEUTICS | 0,530 | +4,74 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| TEMPUS AI | 62,50 | -0,79 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| EDITAS MEDICINE | 2,143 | -1,52 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
Das Unternehmen FORTREA HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-0,76 %) liegt der Kurs bei 13,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.